By administering an in situ injection of three drugs in combination, namely the TLR9 agonist CpG, agonistic anti-OX40 antibody and STING agonist cGAMP, we not only significantly slowed the growth of tumours at the injection site but also altered the growth of distant tumours. Here, STING1 is linked to neoplasm.